Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.
Tuberculosis and Chest Service, Department of Health, Hong Kong SAR, China.
Lung Cancer. 2018 Aug;122:83-87. doi: 10.1016/j.lungcan.2018.05.030. Epub 2018 Jun 1.
Tuberculosis (TB) and lung cancer are important global health threats, each accounting for 1.6 million deaths yearly. The incidence of both conditions remains high in many developing countries, especially in East Asia. There is now epidemiologic evidence that pre-existing TB poses an increased lung cancer risk. The clinical diagnosis of co-existent TB and lung cancer relies on symptoms of infection, typical radiological features and microbiological confirmation, and remains a challenge in both early and late stage lung cancer. The presence of histological granulomatous inflammation in resected lung specimens is not exclusively indicative of TB. The widely accepted systemic chemotherapy and immunotherapy for treating lung cancer are highly relevant to the occurrence of TB and its management. This review addresses the clinical approach to the diagnosis and treatment of TB that co-exists with lung cancer.
结核病(TB)和肺癌是重要的全球健康威胁,每年各导致 160 万人死亡。这两种疾病在许多发展中国家的发病率仍然很高,特别是在东亚。目前有流行病学证据表明,先前存在的结核病会增加患肺癌的风险。同时患有结核病和肺癌的临床诊断依赖于感染症状、典型的影像学特征和微生物学确认,在早期和晚期肺癌中仍然是一个挑战。在切除的肺标本中存在组织学肉芽肿性炎症并不专门表明结核病。广泛接受的治疗肺癌的全身化疗和免疫疗法与结核病的发生及其管理密切相关。这篇综述探讨了同时患有肺癌和结核病的诊断和治疗的临床方法。